

# Stanford

---



## Erik Ames

Clinical Assistant Professor, Pathology

### CLINICAL OFFICE (PRIMARY)

- Department of Pathology

300 Pasteur Dr Rm L235

MC 5324

Stanford, CA 94305

Tel (650) 723-7211 Fax (650) 723-7409

### Bio

---

#### CLINICAL FOCUS

- Anatomic and Clinical Pathology

#### ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Pathology

#### PROFESSIONAL EDUCATION

- Board Certification: Hematopathology, American Board of Pathology (2023)
- Fellowship: Stanford University Hematopathology Fellowship (2023) CA
- Board Certification: Anatomic and Clinical Pathology, American Board of Pathology (2022)
- Residency: Stanford University Pathology Residency (2022) CA
- Medical Education: University of California Davis School of Medicine (2018) CA

### Publications

---

#### PUBLICATIONS

- **Immunophenotyping challenges in the diagnosis of NK-LGLL.** *Blood advances*  
Wilk, A. J., Oak, J. S., Ames, E.  
2026
- **Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.** *Blood cancer journal*  
Rana, M. S., Fernandez-Pol, S., Jensen, A., Hovanky, V., Velayati, A., Oak, J. S., Silva, O., Ames, E., Muffly, L. S., Sahaf, B., Arai, S., Kennedy, V. E., Bharadwaj, et al  
2026
- **Detection of cytogenetically cryptic PML-RARA fusion in acute promyelocytic leukemia by rapid next generation sequencing.** *NPJ precision oncology*  
St Louis, H., Protopsaltis, N., Ames, E., Tanaka, T., Song, W.

2025; 9 (1): 279

- **Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas.** *International journal of molecular sciences*  
Cruz, S. M., Iranpur, K. R., Judge, S. J., Ames, E., Sturgill, I. R., Farley, L. E., Darrow, M. A., Crowley, J. S., Monjazeb, A. M., Murphy, W. J., Canter, R. J.  
2024; 25 (6)
- **Unexpectedly low tacrolimus concentrations attributed to inappropriately labeled water container from the instrument manufacturer.** *Clinical chemistry and laboratory medicine*  
Ames, E., Bowen, R. A.  
2022
- **Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment.** *International review of cell and molecular biology*  
Dunai, C., Ames, E., Ochoa, M. C., Fernandez-Sendin, M., Melero, I., Simonetta, F., Baker, J., Alvarez, M.  
2022; 370: 65-122
- **Polytypic T-cell prolymphocytic leukemia.** *Blood*  
Ames, E., Silva, O.  
2021; 137 (15): 2125
- **Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells** *CANCERS*  
Luna, J. I., Grossenbacher, S. K., Sturgill, I. R., Ames, E., Judge, S. J., Bouzid, L. A., Darrow, M. A., Murphy, W. J., Canter, R. J.  
2019; 11 (1)
- **Sclerosing mucoepidermoid carcinoma with eosinophilia: Cytologic characterization of a rare distinct entity in the thyroid** *DIAGNOSTIC CYTOPATHOLOGY*  
Ames, E., Campbell, M. J., Afify, A., Krane, J. F., Huang, E. C.  
2018; 46 (7): 632-635
- **Immune targeting of cancer stem cells in gastrointestinal oncology** *JOURNAL OF GASTROINTESTINAL ONCOLOGY*  
Canter, R. J., Grossenbacher, S. K., Ames, E., Murphy, W. J.  
2016; 7: S1-S10
- **NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype** *JOURNAL OF IMMUNOLOGY*  
Ames, E., Canter, R. J., Grossenbacher, S. K., Mac, S., Chen, M., Smith, R. C., Hagino, T., Perez-Cunningham, J., Sckisel, G. D., Urayama, S., Monjazeb, A. M., Fragoso, R. C., Sayers, et al  
2015; 195 (8): 4010-4019
- **Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity** *IMMUNITY*  
Sckisel, G. D., Bouchlaka, M. N., Monjazeb, A. M., Crittenden, M., Curti, B. D., Wilkins, D. E. C., Alderson, K. A., Sungur, C. M., Ames, E., Mirsoian, A., Reddy, A., Alexander, W., Soulika, et al  
2015; 43 (2): 240-250
- **Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells** *ONCOIMMUNOLOGY*  
Ames, E., Canter, R. J., Grossenbacher, S. K., Mac, S., Smith, R. C., Monjazeb, A. M., Chen, M., Murphy, W. J.  
2015; 4 (9): e1036212
- **Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma** *BMC CANCER*  
Canter, R. J., Ames, E., Mac, S., Grossenbacher, S. K., Chen, M., Li, C., Borys, D., Smith, R. C., Tellez, J., Sayers, T. J., Monjazeb, A. M., Murphy, W. J.  
2014; 14: 756
- **Regulating ES or Induced Pluripotent Stem Cells by Innate Lymphoid Cells Reply** *TRANSPLANTATION*  
Ames, E., Murphy, W. J.  
2014; 98 (5): E39-E40
- **Treatment of chronic graft-versus-host disease with bortezomib** *BLOOD*  
Pai, C., Chen, M., Mirsoian, A., Grossenbacher, S. K., Tellez, J., Ames, E., Sun, K., Jagdeo, J., Blazar, B. R., Murphy, W. J., Abedi, M.  
2014; 124 (10): 1677-1688

- **Natural Killer Cell Subsets Differentially Reject Embryonic Stem Cells Based on Licensing** *TRANSPLANTATION*  
Perez-Cunningham, J., Ames, E., Smith, R. C., Peter, A. K., Nolta, J. A., Murphy, W. J.  
2014; 97 (10): 992-998
- **Advantages and clinical applications of natural killer cells in cancer immunotherapy** *CANCER IMMUNOLOGY IMMUNOTHERAPY*  
Ames, E., Murphy, W. J.  
2014; 63 (1): 21-28
- **Contrasting Effects of Anti-Ly49A Due to MHC Class I cis Binding on NK Cell-Mediated Allogeneic Bone Marrow Cell Resistance** *JOURNAL OF IMMUNOLOGY*  
Alvarez, M., Sungur, C. M., Ames, E., Anderson, S. K., Pomeroy, C., Murphy, W. J.  
2013; 191 (2): 688-698
- **Murine natural killer cell licensing and regulation by T regulatory cells in viral responses** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Sungur, C. M., Tang-Feldman, Y. J., Ames, E., Alvarez, M., Chen, M., Longo, D. L., Pomeroy, C., Murphy, W. J.  
2013; 110 (18): 7401-7406
- **IFN-gamma Receptor-Deficient Donor T Cells Mediate Protection from Graft-versus-Host Disease and Preserve Graft-versus-Tumor Responses after Allogeneic Bone Marrow Transplantation** *JOURNAL OF IMMUNOLOGY*  
Sun, K., Hsiao, H., Li, M., Ames, E., Bouchlaka, M., Welniak, L. A., Hagino, T., Jagdeo, J., Pai, C., Chen, M., Blazar, B. R., Abedi, M., Murphy, et al  
2012; 189 (4): 2033-2042
- **Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy** *BLOOD*  
Tietze, J. K., Wilkins, D. E. C., Sckisel, G. D., Bouchlaka, M. N., Alderson, K. L., Weiss, J. M., Ames, E., Bruhn, K. W., Craft, N., Wiltout, R. H., Longo, D. L., Lanier, L. L., Blazar, et al  
2012; 119 (13): 3073-3083
- **The Triterpenoid CDDO-Me Promotes Hematopoietic Progenitor Expansion and Myelopoiesis in Mice** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Ames, E., Harouna, S., Meyer, C., Welniak, L. A., Murphy, W. J.  
2012; 18 (3): 396-405
- **Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing** *BLOOD*  
Sun, K., Alvarez, M., Ames, E., Barao, I., Chen, M., Longo, D. L., Redelman, D., Murphy, W. J.  
2012; 119 (6): 1590-1598
- **Mouse Ly49G2(+) NK cells dominate early responses during both immune reconstitution and activation independently of MHC** *BLOOD*  
Barao, I., Alvarez, M., Ames, E., Orr, M. T., Stefanski, H. E., Blazar, B. R., Lanier, L. L., Anderson, S. K., Redelman, D., Murphy, W. J.  
2011; 117 (26): 7032-7041
- **Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition** *CLINICAL AND EXPERIMENTAL IMMUNOLOGY*  
Ames, E., Hallett, W. D., Murphy, W. J.  
2009; 155 (3): 504-513
- **Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Hallett, W. H., Ames, E., Alvarez, M., Barao, I., Taylor, P. A., Blazar, B. R., Murphy, W. J.  
2008; 14 (10): 1088-1099
- **Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition** *JOURNAL OF IMMUNOLOGY*  
Hallett, W. H. D., Ames, E., Motarjemi, M., Barao, I., Shanker, A., Tamang, D. L., Sayers, T. J., Hudig, D., Murphy, W. J.  
2008; 180 (1): 163-170